Pharmacokinetics of Anacetrapib (MK0859) in Patients With Hepatic Insufficiency (MK-0859-039)

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the Area Under the Curve (AUC(0 to infinity)) of anacetrapib.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Anacetrapib; Oxazolidinones

Criteria

Inclusion Criteria:

• Female subjects of reproductive potential test negative for pregnancy and agree to use two acceptable methods of birth control throughout the study

• Subject is in good health

• Subject agrees to refrain from consumption of red wine, grapefruit, orange and apple juices throughout the study

Exclusion Criteria:

• Patient has a history of cancer

• Patient is a nursing mother

• Patient is unable to refrain from or anticipates the use of any prescription or non-prescription medication during the study

• Patient consumes excessive amounts of alcohol or caffeine

• Patient has had major surgery, donated blood or participated in another investigational study within the past 4 weeks